dr. saumil gandhi oligometastatic lung cancer and ways to

BEST OFWCLC

UAE 2021Friday | May 28th | 2021

BIOGRAPHY

Prof. Humaid Al-Shamsi is American and Canadian board certified in Medical Oncology. He completed his medical degree in honors from the University college Cork in Ireland, he completed internal medicine residency and medical oncology fellowship training at McMaster University in Canada.He also completed a fellowship in GI Oncology & Palliative oncology at McMaster University in 2013. He was appointed as an assistant professor in the Department of GI Oncology at MD Anderson Cancer Center, the University of Texas from June 2014 until Dec 2016.He is currently a consultant of oncology and director of Burjeel Cancer Institute Abou Dhabi UAE and holds a professor position at Sharjah University.He is the president of Emirates Oncology Society. Prof. Al-Shamsi has extensive clinical and research experience in solid malignancies and he is a string advocate for palliative care in UAE.

PROF. HUMAID AL-SHAMSIMD(Hon), MRCP(UK), FRCP(C), FACP

Consultant of OncologyPresident of Emirates Oncology Society

Director of Oncology Services - VPS Health

ABIM Board Certified in Internal Medicine and Medical OncologyProfessor - University of Sharjah

PROF. SOLANGE PETERSMD-PhD

Chair Medical OncologyOncology Department – CHUV

Lausanne University, SwitzerlandESMO President

Prof. Solange Peters, MD-PhD, achieved her MD from the Medical School at the University of Lausanne in 1998, following this she attended the Microbiology Institute at the University of Lausanne until 2002, concluding with an MD-PhD thesis on new HIV drug-resistance mechanisms. From 2002-2006, Prof. Peters did her residency in Internal Medicine, followed by a Fellowship at the Multidisciplinary Oncology Centre, both at the University Hospital of Lausanne. In September 2006, she sat the ESMO Examination in Oncology and was awarded the ESMO Best European Exam result. This was shortly followed by the SSMO (Swiss Society of Medical Oncology) oral exam November 2006. In 2013, Prof. Peters received the title of Lausanne University Private Docent (PD-MER) and was appointed Professor and Head of Medical Oncology at the Faculty of Biology and Medicine in Lausanne successively in 2015 and 2016. Prof. Peters is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is building a translational program in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan in Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Prof. Peters’ main field of interest is a new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally-advanced NSCLC as well as clinical and translational cancer immunotherapy. Her current research projects as a chair are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy for the treatment of NSCLC, SCLC, thymic malignancies and mesothelioma, denosumab in advanced NSCLC, ALK, RET, EGFR as well HER2 inhibitors.

SCIENTIFIC PARTNER ENDORSED BY

Dr. Saumil Gandhi is an assistant professor in the department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston where he specializes in treatment of Thoracic malignancies.He completed his undergraduate degree in electrical engineering at the Massachusetts Institute of Technology. He remained at MIT for a master’s degree in electrical engineering and computer science. He then moved to New York for his MD/PhD at the Albert Einstein College of Medicine where he worked on single cell gene expression and breast cancer metastasis under the mentorship of Dr. Rob Singer and John Condeelis. Dr. Gandhi then did his residency training at the University of Pennsylvania in Philadelphia. In 2016, he was recruited to MD Anderson, where his research interests have focused on oligometastatic lung cancer and ways to combine immunotherapy, targeted therapies, and radiation.DR. SAUMIL GANDHI

MD PhD

Assistant ProfessorDepartment of Radiation Oncology

The University of Texas MD Anderson cancer Center, USA

BEST OFWCLC


BIOGRAPHY

Dr. David Dawe received his medical degree from Queen’s University, then moved to Winnipeg to pursue post-graduate training at the University of Manitoba. He completed residencies in Internal Medicine and Medical Oncology at the University of Manitoba, then a Geriatric Thoracic Oncology Fellowship at McMaster University. He has an MSc in Community Health Sciences from the University of Manitoba. He currently holds the Manitoba Medical Service Foundation John Henson Clinical Research Professorship in Population Health and has received research funding from the CancerCare Manitoba Foundation and the Canadian Institutes of Health Research.Dr. Dawe’s research interests lie in the use of clinical and administrative databases to examine outcomes, quality, and disparities in care. One area of potential disparity is the treatment received by older cancer patients and Dr. Dawe is currently examining patterns of care for older patients with cancer to identify opportunities for system improvement and knowledge translation.

DR. DAVID DAWE MSc MD FRCPC

Medical Oncologist, CancerCare Manitoba, Canada

Assistant Professor, Department of Internal Medicine,

Section of Haematology/Oncology, University of Manitoba, Canada

Dr. Peter Ellis is a Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University. He is also Division Head of Medical Oncology at the Juravinski Cancer Centre (JCC). He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney. Dr Ellis moved to Canada in October, 2000. He is an Executive Member of the Canadian Cancer Trials Group (CCTG) Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group. He is also an investigator on several NCIC and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer.

DR. PETER ELLISMBBS MMed(Clin Epi)

PhD FRACP FRCPC

Professor, McMaster UniversityDivision Head of Medical Oncology, Juravinski Cancer Centre (JCC), CA

Dr. Videtic Subbiah, MD is an Associate Professor in the Department of Investigational Cancer Therapeutics (A Phase 1 Program). He is the Center Clinical Medical Director, Center for Targeted Therapy, Division of Cancer Medicine, at The University of MD Anderson Cancer Center. After completing his medical school in India at Sri Ramachandra Medical College and Research Institute, India he completed a combined residency in Internal Medicine and Pediatrics at Case Western Reserve University, MetroHealth, Cleveland Ohio. Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at the UT MD Anderson Cancer Center. Dr. Vivek Subbiah is a Clinical trialist and Physician Investigator at the Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center which is the largest oncology drug development unit in the world. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in antibody-drug conjugates, radiopharmaceuticals, immunoconjugates and basket trials.

DR. VIVEK SUBBIAH MD

Medical Oncologist,MD Anderson Cancer Center, USA


BEST OFWCLC


BIOGRAPHY

Prof. Dean Fennell is Professor & consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Programme based at the University of Leicester/University Hospitals of Leicester NHS Trust. He is an internationally recognised key opinion leader in drug development, a clinical investigator and translational researcher in thoracic oncology, stratified therapy, immuno-oncology and mesothelioma. He has designed and led several investigator-initiated trials from phase 1 through phase III (including CONFIRM (anti-PD1), the first ever positive phase III in relapsed mesothelioma). Prof Fennell is a member of the IASLC mesothelioma taskforce, steering committee for the British Lung Foundation mesothelioma research network, past president of the International mesothelioma interest group, co-author of the UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines and served two terms on the EORTC board. Prof. Fennell is currently the Leicester lead for the ground breaking Cancer Research UK TraceRx lung/Darwin/PEACE and BLF supported MEDUSA phylogenetic studies. Prof. Fennell held two prestigious CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at UCL where he was awarded several prizes. He completed medical training in the London Golden circuit (Hammersmith, Brompton, Guy's, St Thomas's), and completed his specialist training at Barts Hospital. Prof. Fennell has published 143 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature communications, Nature Reviews Cancer, and Proceedings of the National Academy of Sciences (H score 53, with over 11,000 citations)

PROF. DEAN FENNELLPhD FRCP

Chair of Thoracic Medical Oncology, Director, Leicester Mesothelioma

Research ProgrammeCancer Research UK Centre

Experimental Medicine CentreUniversity of Leicester and

University Hospitals of Leicester NHS Trust, UK

Dr. Federico Cappuzzo has been the Director of Medical Oncology at the National Cancer Institute Regina Elena in Rome. In November 1992, he graduated, summa cum laude, in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree summa cum laude in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997. From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA). For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting associate professor in Medical Oncology at University of Colorado in Denver (USA). From January 2010 to April 2016 he was the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno. From April 2016 to September 2020 he was Director of Oncology and Hematology Department at AUSL Romagna in Ravenna.Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Member of the editorial board of Lung Cancer. From 2013 to 2017 he was the Chairman of the Educational Committee of IASLC. He is the author of more than 250 papers in peer-review journals, mainly in translational research in lung cancer.

DR. FEDERICO CAPPUZZOMD

Director of Medical Oncology at National Cancer Institute

Regina Elena, Italy

Dr. Te-Chun Hsia is the Chair and Associated Professor of Department of Respiratory Therapy, Vice-Chair of Department of Internal Medicine, and Director of Intensive Medicine Center in China Medical University Hospital (CMUH). He received MD degree, and Master and PhD degrees of Clinical Medicine, all from China Medical University (CMU). Dr. Hsia serves as an active member and leadership position in multiple academic societies, including Taiwan Lung Cancer Medical Society, Taiwan Hyperbaric Oxygen and Undersea Medical Society, Taiwan Pulmonary and Critical Medical Society, Taiwan Integrated Medical Society, among several others. Dr. Hsia has been principle investigators in many lung cancer clinical trials and INDs, and conducted basic researches in airway disease, lung cancer, SNP, cell line and cancer signal pathway. Dr. Hsia has authored/ co-authored more than 200 scientific publications in peer review journals in these research areas.

DR. TE-CHUN HSIAMD, PhD

Chair, Department of Respiratory Therapy, China Medical University.

Vice-Chair, Department of Internal Medicine and Director, Intensive Medicine Center, China Medical University Hospital,

Taiwan


BEST OFWCLC


BIOGRAPHY

Dr. Abdulaziz Al-Farsi is graduated from College of Medicine SQU in 2001.

He joined Internal Medicine Program OMSB in 2003.

He became Member of Royal College of physicians UK in 2006 and joined Department of Medical Oncology in Royal Hospital that year.

He completed his studies in McMaster University, Hamilton, Canada where he finished Internal Medicine and Medical Oncology Residency from 2010 till 2015.

He completed research and clinical fellowship in thoracic malignancies at the same university in June 2017.

He works currently as Senior Consultant and Chairperson of Tumor Board, National Oncology Center, Muscat, Oman.

DR. ABDULAZIZ AL-FARSI MD

Head of Medical Oncology Royal Hospital, OmanOCA Board Member

Dr Muath Al-Nassar completed the medical oncology fellowship from University of Western Ontario, Canada in 2016.He obtained the medical degree from Kuwait University and the Rnternal residency Training from Kuwait Institute for Medical Specialization in 2007.He is currently the Head of Thoracic and Sarcoma Unit in Kuwait Cancer Control Center

DR. MUATH AL-NASSAR MD

Consultant Medical Oncologist Head of Thoracic and Sarcoma UnitKuwait Cancer Control Center,

Kuwait

Dr. Dorai Ramanathan is a highly qualified Oncologist from the United Kingdom with over 13 years’ experience in managing adult cancer patients. His expertises is in Chemotherapy and Radiotherapy for all adult solid tumors. His sites of special interest are Breast, Lung, Gynaecological and Colon cancer. He has experience in prescribing Chemotherapy, targeted treatment and Immunotherapy. He is also a qualified Radiation Oncologist from UK, and is an expert in delivering treatment in techniques such as IMRT (Intensity Modulated Radiotherapy) and IGRT (Image Guided Radiotherapy).

DR. DORAI RAMANATHAN MBBS, MRCP(UK),

MSc (onco), FRCR (UK),CCT (UK), ESMO certified

Consultant Medical OncologistAl Zahra Hospital, UAE


BEST OFWCLC


BIOGRAPHY

Dr. Farooq Latif is currently working as a consultant medical oncologist in Dubai Hospital. After graduation, Dr Farooq completed general internal medicine training in North Yorkshire, UK and attained MRCP in 2007. He then completed clinical oncology training in Liverpool, Merseyside leading to CCT. Dr Farooq became a fellow of Royal college of radiologist (FRCR), faculty of clinical oncology in 2013 and was subsequently awarded fellowship of Royal college of Physicians of Glasgow FRCP(Glasg) and fellowship of Royal college of physicians of Edinburgh FRCP(Edin). He worked as a consultant clinical oncologist in North Wales cancer centre and Royal stoke university hospital, Midlands, UK. He has keen interest in teaching and research and has published in peer-reviewed journals.

DR. FAROOQ LATIFMD, American Board-Certified

Consultant Medical Oncologist, Dubai Hospital, UAE

Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience.

Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995, 1996 respectively.

Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center.

Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name.

He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials.

DR. HASSAN GHAZALMD, American Board-Certified

Consultant Medical Oncologist & Consultant Clinical Hematologist

King's College Hospital, UAE

Dr. Falah Al-Khatib graduated from the faculty of medicine, Ain Shamis University in 1969. He completed his training and residency in general and thoracic surgery in Iraq from 1970 to 1975. Later he changed his specialty to radiotherapy and had his DMRT in 1980 and obtained his fellowship FFRRCSI in 1984.Dr Al-Khatib worked as consultant and chief of radiotherapy at Tawam Hospital between 1986 and 2007 and was involved in the management of more than 12,000 patients. He helped to establish Tawam Hospital as the main cancer center in the UAE and in the region; He started hospital-based tumor registry in 1986 which later became the foundation for the UAE cancer registry in 1998. During his time at Tawam Hospital, he created many multidisciplinary clinics for different cancer types like breast, gynecological, H+N and thyroid. He has been a member of many national, regional and international committees and he is a member of the UAE National Cancer committee.On January 2011, Dr Al-Khatib started working a consultant clinical oncologist (radiation oncology and medical oncology) at Mediclininc City Hospital, Dubai UAE.Dr Al-Khatib is the Vice President of the Emirates Oncology Society

DR. FALAH AL-KHATIBMD, FRCSI

Consultant Oncologist and Radiotherapist

at Mediclinic City Hospital, UAEEOS Vice President


BEST OFWCLC


BIOGRAPHY

Dr. Hassan Jaafar, is a medical oncology consultant in SKSH. He received his M. B. Ch. B (MD) in 1992, the internal medicine board in 1997, and he passed the Arab board exam in internal medicine, he completed a 3 years of fellowship in hematology- oncology and certified as a medical hematologist oncologist from American university hospital of Beirut in the year 2000.Worked as a medical oncology consultant at Tawam hospital (affiliated with Johns Hopkins) UAE, from the year 2000 till feb-2018He became an Assistant professor in the department of internal medicine, college of medicine and health sciences of the UAEEU as he lectured in Al-Ain university faculty of medicine between 2008-2018 He moved to Sheikh Khalifa Speciality Hospital (SKSH) operated by Seoul National University Hospital (SNUH) in Ras Alkhaima in March 2018He is the author and co-author of more than 50 peer-reviewed papers and abstracts.He is involved in more than 6 ongoing phase III trials regional and international and he is a member of the GOG (gulf oncology group) that conducted 2 phase II trialsHe is member in many societies (UAE Oncology and radiation therapy association, Emirate of Gyn-oncology group, Lebanese hematology and oncology association, ESMO European society of medical oncology, ASCO American society of clinical oncology, and Member in the NCCN MENA subcommittee for HCC, Lung ca) Elected as a Member of the Scientific and Education Committee of the Arab Collaborative Hematology and Oncology Group (ACHOG), GIST working Group, member of the Africa Middle East Cancer Research Intergroup (AMCI)

DR. HASSAN JAAFARMD

Medical Oncology ConsultantSheikh Khalifa Specialty Hospital

Ras Al Khaimah, UAE

Dr. Ibrahim Abu-Gheida joined VPS healthcare and Burjeel Medical City coming from the prestigious MD Anderson Cancer Center in Houston Texas. He completed his undergraduate training where he earned a Bachelor of Science with honors degree from the American University of Beirut. Following which Dr. Abu-Gheida completed his Medical School training at the American University of Beirut Medical Center. He later continued and joined the Department of Internal Medicine at the American University of Beirut. Then did his training in the Department of Radiation Oncology at the American University of Beirut Medical Center, where he served also as the chief resident. During his Training, Dr. Abu-Gheida completed a Harvard-affiliated NIH-funded research program as well. After his residency, Dr. Ibrahim went to Cleveland Clinic / Ohio, where he was appointed as an Advanced Clinical Radiation Oncology Fellow. Dr. Abu-Gheida went and joined the University of Texas MD Anderson Cancer Center where he sub-specialized in treating Breast, gastrointestinal, and genitourinary cancers. Dr. Ibrahim has more than 25 peer-reviewed papers in the prestigious medical journal including the American Society of Radiation Oncology official journal - International Journal of Radiation Oncology Biology and Physics (RED), Nature, Journal of Clinical Oncology (JCO), and several others. He is also the primary author of several book chapters published in prestigious books. Dr. Abu-Gheida currently severs as the founding head of the department of radiation oncology at Burjeel Medical City in Abu-Dhabi, and an adjust assistant professor in the United Arab Emirates University.

DR. IBRAHIM ABU-GHEIDAMD

Head of Department of Radiation Oncology

Burjeel Medical City, UAEAdjunct Assistant Professor,

College of Medicine and Health Sciences,

United Arab Emirates University

Dr. Ramanujam Singarachari ( Dr Ram) came to SKMC in 2009 from Auckland City Hospital, New Zealand after 3 years of higher training in Medical Oncology. He has completed his Medical Oncology Super-Specialty Degree (DM) in 2001 from Cancer Institute, Chennai, India and subsequently worked as faculty at regional cancer centers in India, before joining as senior staff specialist at Dubai Hospital, UAE. He is certified and recertified (2019) from European Society of Medical Oncology. He is also certified in Medical Oncology by the Federation of Royal Colleges of Physicians of the United Kingdom and the Association of Cancer Physicians. His areas of interest are GI cancers, Breast cancers, CNS cancers and Palliative Care.DR. RAMANUJAM

SINGARACHARI MD DM

Medical Oncology,Sheikh Shakhbout Medical City,

UAE


BEST OFWCLC


BIOGRAPHY

Dr. Shaheenah Dawood is Consultant Medical Oncologist and Associate Professor in Clinical Oncology in the United Arab Emirates.

She currently leads the oncology clinical trials program at Mediclinic City Hospital, Dubai & Parkview, Dubai, UAE

DR. SHAHEENAH DAWOODMD

Consultant in Medical Oncology,Mediclinic City Hospital

& Parkview, UAE

Dr. Syed Hammad Tirmazy is a Consultant Clinical Oncologist and Head of Oncology at Dubai Hospital, DHA.He has substantive experience in managing adult solid cancers and has been involved in multiple international clinical trials.Before moving to Dubai in 2016, he was working as Consultant Clinical Oncologist in west midlands region UK.After completing his graduation, he moved to UK in 2003, he initially completed internal medicine training and MRCP and subsequently attained training in Clinical Oncology and worked in internationally renowned oncology centers in UK including Queen Elizabeth Hospital Birmingham.He completed Master’s in Clinical Oncology from university of Birmingham, FRCR Clinical Oncology from RCR London and has CCT in Clinical Oncology. He also attained FRCP Glasgow.

DR. SYED HAMMAD TIRMAZY MRCP, FRCP, FRCR

MSc Clinical Oncology, CCT UKConsultant Clinical Oncologist

and Head of Oncology, Dubai Hospital, UAE

EOS Cultural Committee Chairperson


dr. saumil gandhi oligometastatic lung cancer and ways to

Documents